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Abstract
DNA methylation and copy number in the genomes of
three immortalized prostate epithelial and five cancer
cell lines (LNCaP, PC3, PC3M, PC3M-Pro4, and PC3M-
LN4) were compared using a microarray-based tech-
nique. Genomic DNA is cut with a methylation-sensitive
enzyme HpaII, followed by linker ligation, polymerase
chain reaction (PCR) amplification, labeling, and hy-
bridization to an array of promoter sequences. Only
those parts of the genomic DNA that have unmethyl-
ated restriction sites within a few hundred base pairs
generate PCR products detectable on an array. Of
2732 promoter sequences on a test array, 504 (18.5%)
showed differential hybridization between immortal-
ized prostate epithelial and cancer cell lines. Among
candidate hypermethylated genes in cancer-derived
lines, there were eight (CD44, CDKN1A, ESR1, PLAU,
RARB, SFN, TNFRSF6, and TSPY) previously observed
in prostate cancer and 13 previously known methyl-
ation targets in other cancers (ARHI, bcl-2, BRCA1,
CDKN2C, GADD45A, MTAP, PGR, SLC26A4, SPARC,
SYK, TJP2, UCHL1, and WIT-1). The majority of genes
that appear to be both differentially methylated and
differentially regulated between prostate epithelial and
cancer cell lines are novel methylation targets, includ-
ing PAK6, RAD50, TLX3, PIR51, MAP2K5, INSR, FBN1,
and GG2-1, representing a rich new source of candi-
date genes used to study the role of DNA methylation
in prostate tumors.
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Introduction
Aberrant DNA methylation of CpG sites is among the
earliest and most frequent alterations in cancer [1,2]. In
many cases, DNA methylation at CpG, in or near the
promoter or first exon of a gene, is associated with gene
‘‘silencing.’’ Multiple different methylases and proteins that
either bind methylated DNA or unmethylated CpG are
associated with: 1) transmitting the methylation status to
other proteins in the chromatin; 2) maintaining the DNA meth-
ylation profile during replication; and 3) changing the methyla-
tion profile during differentiation of cells. Thus, as a result of
methylation at multiple CpG sequences, chromatin structure in
the promoter may be altered, preventing normal interaction
with transcriptional machinery. If this occurs in genes critical to
growth inhibition, the resulting silencing of transcription could
promote tumor growth. Hypermethylation has been shown to
be commonly associated with transcriptional inactivation for
classic tumor suppressor genes, genes important for cell cycle
regulation, and genes that mediate DNA mismatch repair [3].
At present, several molecular biology methods are routinely
used to determine the methylation status of a CpG island.
Among these, bisulfite nucleotide sequencing is a technique
used for a detailed mapping of methylated cytosine residues
within a gene promoter [4,5]. Restriction landmark genome
scanning (RLGS) is a two-dimensional gel electrophoresis
method that has been used to study genetic and epigenetic
changes, including DNA methylation [6–8]. Microarrays allow
many DNA sequences to be queried in parallel especially
when the targets can be made into reduced complexity rep-
resentations [9,10]. Using this method, the binding profile of
proteins that interact specifically with methylated DNA se-
quences can be detected by chromatin immunoprecipitation
(ChIP) [11–14]. Alternatively, DNA methylation can be detected
directly by cleavage of the genome with a 5-methylcytosine–
sensitive restriction enzyme. In one method, methylation at the
methylation-sensitive restriction sites for BstUI and HpaII pre-
serves certain methyl-insensitive MseI fragments that are
otherwise cleaved if the site is unmethylated. Difference is
amplified polymerase chain reaction (PCR) products indicate
differences in BstUI and HpaII methylation [15–17].
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Another method is to cleave with a methyl-sensitive re-
striction enzyme, size fractionate, and hybridize fractions to
a microarray. As methylation will change the size of cleav-
age products, they will be in a different fraction [18–20]. A
protocol for detecting methylation differences between two
genomes using this class of methods is outlined in Figure 1.
The protocol relies on the occurrence of two methyl-sensitive
cleavage sites in close proximity. If the restriction sites are
both unmethylated, they can be cleaved and primers can
be ligated. When the distance between the ligated primers
is short enough, the fragment can be amplified efficiently
by PCR. If, on other hand, the DNA is methylated at one of
the cleavage sites, it will not be cut at that site and a longer
fragment will be produced. In most cases, this longer frag-
ment will be sufficiently long that the PCR of the frag-
ment does not occur efficiently. During PCR, thousands of
cleavage– ligation fragments from unmethylated parts of
the genome amplify with varying efficiencies, and their rep-
resentation in the final pool of amplified products depends
on the efficiency of their amplification. However, the effi-
ciency of amplification of any particular fragment should
remain similar between experiments. Thus, in general, dif-
ferences in the starting amount of a particular fragment will
be preserved in the same ratio after PCR. The reduction in
complexity while preserving ratios relies on the same princi-
ples as those previously published methods for compara-
tive genomic hybridization (CGH) [9] and expression analysis
[10]. These differences are measured on an array of genomic
regions; in this case, we monitored methylation changes on
an array 2732 promoter–first exon regions [21,22].
The method is applied to eight prostate epithelial cell
lines—three immortalized epithelial lines and five lines de-
rived from cancers. Differences in copy number can also be
detected in this and all the other high-throughput methods
referenced here. Here, copy number changes, which are
also of interest, are distinguished from methylation changes
by a variety methods, such as methylation-specific PCR
(MSP), and by 5-aza-2V-deoxycytidine (DAC) treatment.
Someof themethylation differences revealed have frequently
been observed in prostate cancer, includingCD44,CDKN1A,
ESR1,PLAU,RARB,SFN, TNFRSF6, andTSPY, and others
are previously known methylation targets in other cancers,
including ARHI, bcl-2, BRCA1, CDKN2C, MTAP, PGR,
SLC26A4, SPARC, SYK, TJP2, UCHL1, and WIT-1. How-
ever, most of the methylation candidates are potentially new
targets that will need to be confirmed in tumors.
Materials and Methods
Cell Culture
Human prostate epithelial cell lines 267B1, RWPE-1, and
Ml-csv40 were kindly provided by Dr. J. Rhim (U.S. Navy
Hospital, Bethesda, MD). LNCaP was obtained from ATCC
(Manassas, VA), and PC3, PC3M, PC3M-Pro4, and PC3M-
LN4 were kindly provided by Dr. Isaiah J. Fidler (M. D.
Anderson Hospital Cancer Center, Houston, TX). Cells
were cultured in RPMI medium containing 10% fetal bovine
serum and 4 mM L-glutamine. LNCaP was also cultured in
the presence of mock (PBS) or DAC (1 mm,medium changed
every 24 hours; Sigma-Aldrich Co., St. Louis, MO) and the
cells were harvested at 24 hours after the third dose.
Genomic DNA and total RNA were extracted from cell lines
using DNeasy Tissue Kit and RNeasy Mini Kit (Qiagen, Inc.,
Valencia, CA), respectively.
Preparation of Promoter Microarray
A detailed description of the promoter array used here has
been published [21,22]. Briefly, human promoter sequences
(1000 bp upstream and 500 bp downstream from transcrip-
tion initiation site) were retrieved batchwise from http://
genome.ucsc.edu/. PCR primers were selected using an
in-house version of Primer3 (http://www.broad.mit.edu/
genome_software/other/primer3.html). Promoter fragments
with an average length of 1.2 kb were amplified, purified,
and spotted onto UltraGAPS-coated slides (Corning, Inc.,
Corning, NY) in the presence of 50% DMSO. The promoter
microarray contains triplicate spots of 3083 promoter se-
quences (2732 when duplicates are considered), 787 non-
promoter controls, and 192 nonhuman controls. Many of
the promoters on the array are from genes of particular rele-
vance to cancer, and the array includes promoters from most
of the genes that are known to be regulated by methylation
in cancer. The array is freely available to collaborators.
Methylation Microarray Analysis
HpaII (New England Biolabs, Beverly, MA) digestion was
performed in 20 ml containing 0.5 mg of genomic DNA and
5 U of HpaII for 2 hours at 37jC. Ten-fold overdigestion, plus
monitoring of the digestion of lambda DNAmixed with human
genomic DNA in a parallel reaction, were used to minimize
the possibility of partial digestion. The digested fragments
Figure 1. Schematic of the protocol for detecting differences in HpaII
fragment amplification between samples.
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are ligated with linker Meth_1a1/Meth_1a2/Meth_4a1/
Meth_4a2 (20 pmol each) in the presence of 20 U/ml of T4
DNA ligase (New England Biolaboratories) and 1 mM ATP
(Amersham Biosciences, Piscataway, NJ) at room temper-
ature for 4 hours. The oligonucleotide sequences were as
follows: Meth_1a1, 5V-AAGTATCGGAGGAGTCTTTGTTA-
3V; Meth_1a2, 5V-phosphate-CGTAACAAAGACTCC-
TCCGATACTT-amine-3V; Meth_4a1, 5V-TCTCTTGA-
AGAGTAACTTGTTGG-3V; Meth_4a2, 5V-phosphate-
CGCCAACAAGTTACTCTTCAAGAGA-amine-3V. Meth_1a1
and Meth_1a2 are mixed, heated to 95jC for 5 minutes, and
cooled down to room temperature before ligation. Meth_4a1
and Meth_4a2 were treated similarly.
Repetitive DNA sequences were depleted from the ligated
DNA using a previously described subtraction hybridization
protocol [23] with some modification. Ten micrograms of
humanCot1 DNA (Invitrogen Corporation, Carlsbad, CA) con-
taining enriched repetitive sequences was biotin-labeled
using the BiotinULS Labeling Kit (Fermentas Life Sciences,
Hanover, MD) at 85jC for 30 minutes. Cot1 DNA was
purified using ethanol precipitation and dissolved with 100 ml
of binding buffer TEN100 (10 mM Tris–HCl, 1 mM EDTA,
100 mM NaCl, pH 7.5). One hundred microliters (1 mg) of
streptavidin magnetic particles was prepared according to
the manufacturer’s instructions (F. Hoffmann-La Roche Ltd.,
Alameda, CA), added to the biotin-labeled Cot1 DNA, and
incubated at room temperature for 15 minutes. Tubes were
applied to a magnetic particle separator (F. Hoffmann-La
Roche Ltd.) and the supernatant was removed. Fresh bind-
ing buffer TEN100 was added, and incubation continued at
room temperature for 15 minutes, followed by removal of the
supernatant. The particles were washed twice with TEN100
(10 mM Tris–HCl, 1 mM EDTA, 1000 mM NaCl, pH 7.5).
HpaII digested–ligated DNA was placed in the tube and
adjusted to 100 ml with 6 SSC and 0.1% SDS. The mixture
of ligated genomic DNA and biotinylatedCot1 DNA, attached
to streptavidin beads, was denatured by boiling for 10 min-
utes and the mixture was hybridized at 65jC overnight in a
rotating hybridization oven. After hybridization, 100 ml (1 mg)
of streptavidin magnetic particles was prepared according
to the manufacturer’s instructions, added to the hybridiza-
tion mixture with an extra 200 ml of TEN100, and incubated
at room temperature for 30 minutes. Tubes were applied to a
magnetic particle separator and the supernatant was aspi-
rated. This supernatant was incubated with another 1 mg of
streptavidin magnetic particles again at room temperature
for 30 minutes. After the incubation, the supernatant was
aspirated and purified using a MinElute PCR purification kit
(Qiagen, Inc.).
Target DNA was amplified with 20 ng of DNA per 50 ml
of reaction with 0.4 mM of each oligonucleotide, Meth_1p
(5V-GTATCGGAGGAGTCTTTGTTACGG-3V) and Meth_4p
(5V-CTTGAAGAGTAACTTGTTGGCGG-3V), with Ex Taq poly-
merase (Takara Bio, Inc., Madison, WI) at 60 seconds at
95jC; 20 cycles of 15 seconds at 95jC, 15 seconds at 63jC,
and 30 seconds at 72jC; 7 min at 72jC; and then at 4jC.
PCR products were purified using a MinElute PCR purifica-
tion kit (Qiagen, Inc.).
Hybridization of Amplified HpaII Fragments to the Array
and Data Analysis
PCR products were purified and 1 mg of DNA was labeled
with Cy3 or Cy5 using Ready-To-Go DNA Labeling Beads
(Amersham Biosciences). PCR products from 267B1 DNA
were used as a reference and all other cell line PCR products
were cohybridized with it. Labeling and hybridization were
all duplicated with dye swapping, and experiments were
repeated at least once from the very beginning. In addition,
data were collected on three arrays per slide. The Cy3/Cy5–
labeled targets were hybridized overnight to human pro-
moter array slide at 42jC in the presence of 5 SSC, 0.1%
SDS, 25% formamide, and Cot1 blocking solution. Slides
were washed following the Corning protocol (Corning, Inc.)
and scanned with a Perkin Elmer Scanarray Express Micro-
array Scanner (Perkin Elmer, Inc., Wellesley, MA). Micro-
array data were retrieved with a Quantarray Microarray
Analysis Software (Perkin Elmer, Inc.). Methylation micro-
array data have been deposited in the Geo database (http://
www.ncbi.nlm.nih.gov/geo/; GEO accession no. GSE951).
Statistical microarray data analysis was performed using
R-language and the Limma package from www.bioconductor.
org [24]. Microarray data were normalized with print-tip
loess or composite within-array normalization, followed by
between-array normalization, before statistical analysis [25].
A moderated t-test was used for statistical analysis [26].
Genesis software was used to cluster genes as well as to
visualize and represent data [27].
Print-tip loess normalization was applied based on the
assumption that the spot intensities generated from two
samples were similarly distributed. However, in the demeth-
ylation experiments using DAC, all the changes should be
in one direction due to demethylation. Composite normali-
zation used 88 promoters that showed significantly in-
creased hybridization signals in LNCaP when compared
with at least one of the three normal prostate cell lines:
These already ‘‘unmethylated’’ promoters should not change
during demethylation treatment.
The microarray hybridization data were sorted based on
their chromosome location and analyzed as CGHs. The
CGH microarray data were subjected to statistical analysis
as described by Clark et al. [28] with some modification. We
first constructed a quadratic loess curve, which can be
viewed as a locally weighted polynomial regression curve
through each data set. We then identified those regions in
which contiguous segments of the loess curve were consis-
tently greater than (or less than) 1.8 SD away from the mean
of the all the data points. Having located these regions of
interest, we used the Mann–Whitney U test to determine
whether each selected region differed significantly (P < .001)
from the set of data points from regions that had not been
selected for examination by this test. Alternative analysis
methods are also available (e.g., Ref. [29]).
MSP
The methylation status of 14 randomly picked genes,
which were observed as differential methylated between
PC3M and 267B1, was also determined by MSP. In brief,
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2 mg of genomic DNA was treated with sodium bisulfite for
16 hours using an EZ DNA Methylation Kit (Zymo Research,
Orange, CA). After purification, 1 ml of the aliquot was used
as a template for each PCR reaction. The MSP primers were
designed with the MethPrimer program [30] and primer in-
formation is presented in Table 1. Semiquantitative PCR
was performed in an ABI PRISM 7900 Sequence Detection
System (Applied Biosystems, Foster City, CA). Each 15 ml of
reaction contained 100 ng of DNA, 1 HotStartTaq PCR
Buffer (with 1.5 mM MgCl2; Qiagen, Inc.), 1:25,000 dilution
Table 1. Primers for Methylation-Specific Semiquantitiative PCR.
RefSeq ID Gene Symbol Expression Ratio (Log2) Primer Information*
Putative hypermethylated promoters in PC3M relative to 267B1
NM_000082 CKN1 0.75 M-FW: GTTAATTTTCGAGAAAGGAATTAGC
RW: AAAATATCTTCAACGCCTCGAC
U-FW: ATGTTAATTTTTGAGAAAGGAATTAGTG
RW: AAAAAAAATATCTTCAACACCTCAAC
NM_001008 RPS4Yy 6.36 M-FW: GTTATTTAGGTTGGAGTGTAGTGGC
RW: GAATCACGAAATCAAAAAATCG
U-FW: GTTATTTAGGTTGGAGTGTAGTGGTG
RW: CAAATCACAAAATCAAAAAATCAAA
NM_003118 SPARCy,z 7.16 M-FW: GATATTTTCGTTTACGTCGTTAGTTC
RW: AAAAAATAAAAAAATACTCCCCCG
U-FW: GATATTTTTGTTTATGTTGTTAGTTTGT
RW: AAAAATAAAAAAATACTCCCCCAAA
NM_003206 TCF21 NA M-FW: AATATGTTTATCGGTTTTTTTAGCG
RW: TTAAAACTCTCCTCGATACTCTCGT
U-FW: TTTAAATATGTTTATTGGTTTTTTTAGTGA
RW: CAATTAAAACTCTCCTCAATACTCTCATT
NM_003999 OSMR 2.52 M-FW: ATTTTGGTTAATACGGTGAAATTTC
RW: CCAAACTAAAATACAATAACGCGAT
U-FW: TTTTGGTTAATATGGTGAAATTTTGT
RW: TCACCCAAACTAAAATACAATAACACA
NM_004701 CCNB2 1.78 M-FW: GTTAAAATTTAGAGGCGTTTTACGT
RW: ACGTTTAATTATCACAACAACCGAT
U-FW: TTTTGTTAAAATTTAGAGGTGTTTTATGT
RW: CACATTTAATTATCACAACAACCAAT
NM_005509 DMXL1 1.37 M-FW: ATTTCGTTTAGGGATTTGGAAATAC
RW: AAACTACAAATCCCAATATACACCG
U-FW: TTTTGTTTAGGGATTTGGAAATATG
RW: AAACTACAAATCCCAATATACACCACT
NM_005732 RAD50 2.69 M-FW: ATTTTTTTGATTTTGAGATTCGC
RW: GATCCGAAACATATTTACAAACGTT
U-FW: ATTTTTTTGATTTTGAGATTTGTGG
RW: TCAATCCAAAACATATTTACAAACATT
NM_005983 SKP2 1.72 M-FW: TATTTCGTGGGTCGATTAGTTTC
RW: ACTAAAAATTATAATTTCCGTCCCG
U-FW: TATTTTGTGGGTTGATTAGTTTTGT
RW: ACTAAAAATTATAATTTCCATCCCACT
NM_006479 PIR51 1.97 M-FW: GTATAAATTCGGTTTTGGTGGATC
RW: CAAATTCTTATTAACTTCAACGACGA
U-FW: GTATAAATTTGGTTTTGGTGGATTG
RW: TTCTCAAATTCTTATTAACTTCAACAACA
NM_014350 GG2-1 1.94 M-FW: GTTTGGAGTATTAGTGTTCGTTCG
RW: CGAAACCTTTTAAAAAAAATAAAACG
U-FW: GTTTGGAGTATTAGTGTTTGTTTGG
RW: CAAAACCTTTTAAAAAAAATAAAACAAC
NM_021025 TLX3 NA M-FW: GTTGTGGTTCGGGTTTTAATATTC
RW: CTACCGCAACCATTAACTACGAT
U-FW: GTTGTGGTTTGGGTTTTAATATTTG
RW: TCCTACCACAACCATTAACTACAAT
NM_024501 HOXD1 1.61 M-FW: TTTTAGTGAAAGTAAGCGTCGTATC
RW: CTATCCCTCGCAATTTATAACGA
U-FW: TTTTTAGTGAAAGTAAGTGTTGTATTGG
RW: TCTTCTATCCCTCACAATTTATAACAAC
Putative hypomethylated promoters in PC3M relative to 267B1
NM_006142 SFNz 5.60 M-FW: TAAGTTGGTAGAGTAGGTCGAACGT
RW: CTAAAAACAAATTTCGCTCTTCG
U-FW: GGTTAAGTTGGTAGAGTAGGTTGAATG
RW: CTACTAAAAACAAATTTCACTCTTCACA
*M: primer designed to amplify methylated DNA; U: primer designed to amplify unmethylated DNA.
yGene that does not have a CpG island within the amplified promoter region.
zGene already known as a methylation target in cancer.
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of SybrGreen I (Molecular Probes, Eugene, OR), 0.35 mM
6-ROX (Molecular Probes), 0.2 mM dNTPs, 4 mM MgCl2,
0.025 U/ml HotStartTaq DNA polymerase (Qiagen, Inc.), and
0.8 mM of each primer. Semiquantitative PCR was performed
at 95jC for 15 minutes, 50 cycles of 95jC for 15 seconds,
60jC for 15 seconds, and 72jC for 30 seconds; followed by a
dissociation stage (95jC for 15 seconds, 60jC for 15 sec-
onds, and 95jC for 15 seconds).
Gene Expression Profiling
Affymetrix U133A chips (Affymetrix, Inc., SantaClara, CA)
were used to profile gene expression levels for the 267B1
and PC3M cell lines. Ten micrograms of total RNA of 267B1
and PC3M was prepared using a Qiagen RNeasy Mini
kit. Labeling and scanning procedure followed Affymetrix’s
standard procedure (http://www.affymetrix.com/support/
technical/manual/expression_manual.affx). A gene was con-
sidered to be differentially expressed between two different
samples when expression was ‘‘called present’’ in at least
one sample under default parameters and there was a two-
fold or greater change in net fluorescence between samples.
Results and Discussion
Immortalized Normal Prostate Epithelial Cells and Cancer
Cell Lines
Total genomic DNA from eight prostate epithelial cell lines
were compared using the protocol in Figure 1: DNA was
digested with HpaII, then primers were ligated and PCR-
amplified. The PCR products were hybridized to an array of
promoter sequences. Mlcsv40 and 267B1 are neonatal pros-
tate lineages immortalized with the SV40 early region genes
(unpublished and Ref. [31]), RWPE-1 is an adult human
prostatic epithelial cell line immortalized with human papillo-
mavirus 18 [32]. PC3M is a liver metastatic derivative of one
of the most heavily studied prostate cancer cell lines PC3
[33]. PC3M-LN4 and PC3M-Pro4 are metastatic and less
metastatic derivatives, respectively, of PC3M [34]. LNCaP is
a human prostate cancer cell line established from a lymph
node metastasis [35]. All these lines were expected to
resemble each other in overall methylation profile because
all cell lines are derived from prostate epithelium. However,
we expected to uncover some DNA methylation differences,
as the cell lines are clearly different in phenotype, with some
Figure 2. Estimation of data reproducibility and significance of differences. M: log base 2 ratio of each spot after print-tip loess normalization and scale between-
array normalization. (A) Average of two channels’ log intensities of each spot; a measurement of the overall brightness of the spot. All data involved at least six
arrays. The P value is for the moderated t-test. The most significant changes are represented by open circles. (A) M–A plot, hybridization of amplified HpaII
fragments from 267B1 vs 267B1. (B) M–p plot, hybridization of amplified HpaII fragments from 267B1 vs 267B1. (C) M–A plot, hybridization of amplified HpaII
fragments from PC3M vs 267B1. (D) M–p plot, hybridization of amplified HpaII fragments from PC3M vs 267B1.
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being derived from either neonate or adult normal epithelium
and some from adult epithelial tumors. Furthermore, a recent
study has indicated that prostate cancer cell lines may
possess the same ‘‘hypermethylation fingerprint’’ as primary
and metastatic prostate cancers [36].
To ensure the reproducibility of the protocol, identical
samples of genomic DNA from the same cell line were
processed separately on separate days. A comparison for
267B1 is presented as an example in Figure 2, A and B.
Figure 2A is an M–A plot, which were constructed with
M = log2R  log2G and A = (log2R + log2G) / 2, where R
is the intensity of the scanner output signal for the experi-
mental sample fluorophore (channel 2, Ch2) and G is the
scanner output signal for the reference sample fluorophore
(channel 1, Ch1) on the background-subtracted, normalized,
and scaled channel intensities. Statistically significant, differ-
entially hybridized DNA was identified by a t-test. The distri-
bution of the corresponding P values as a function of M was
summarized in a volcano plot (M–p plot; Figure 2B). Essen-
tially 99.9% (2729/2732) of the ratios between the two
channels was less than 1.5-fold and had P values less than
.001. This experiment was used to set a threshold for other
experiments in which a ratio of at least 1.5-fold and a P value
less than .001 were used. This conservative threshold en-
sures that the hybridization differences between cell lines
that are discussed here are likely to be real, although these
stringent criteria alsomean that many real differences inmeth-
ylation may not be noted, as they are below this threshold.
Differential Array Hybridization between Cell Lines
Figure 2, C and D shows M–A and M–p plots of 267B1
and PC3M as an example of a comparison between cell
lines. Fifty-six genes, including 50 genes that have CpG
islands within the promoter region, are hybridized more in
Figure 3. Effects of methylation inhibitor (DAC) on methylation status of LNCaP. M–p plots, HpaII fragment hybridization pattern of LNCaP before and after treated
with DAC. M: log base 2 ratio of each spot after composite normalization and scale between-array normalization. The P value is from a moderated t-test. The most
significant changes are represented by open circles. (A) M–p plot for all promoters. (B) M–p plot for 191 promoters putatively hypermethylated in LNCaP relative
to at least one of the three normal prostate cell lines.
Figure 4. Detection of DNA methylation changes using methylation-specific semiquantitative PCR. Fourteen promoters that displayed possible differential
methylation in the array assay between 267B1 and PC3M (Table 1) were investigated by methylation-specific semiquantitative PCR. The proportion of methylation
for each promoter is calculated.
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267B1 than in PC3M, consistent with more methylation or
lower copy number in PC3M. Conversely, 30 genes, includ-
ing 14 genes that have CpG islands within the promoter
region, are significantly hybridized to a greater extent in PC3M
(P < .001, ratio > 1.5-fold). It is noteworthy that the method
is capable of detecting hybridization changes in any gene
that has the appropriate restriction sites, regardless of
whether it has a CpG island. Furthermore, it is clear that
many genes that do not have CpG islands within the proxi-
mal part of the promoter nevertheless showed changes in
hybridization, possibly due to methylation changes, but also
possibly due to copy number changes or a point mutation in a
Figure 5. Hierarchical cluster of hybridized, amplified HpaII fragments for eight cell lines. (A) A total of 504 promoters, which are statistical differentially hybridized
between at least one of the five prostate cancer cell lines (LNCaP, PC3, PC3M, PC3M-Pro4, and PC3M-LN4) and at least one of the three relative normal prostate
cell lines (RWPE-1, 267B1, and Mlcsv40), is shown. The normalized hybridization ratios of these cell lines relative to RWPE-1 were used for hierarchical clustering.
Red indicates higher HpaII fragment hybridization relative to RWPE-1, which usually indicates less methylation or a higher copy number. Green indicates lower
hybridization, which usually indicates greater methylation or a lower copy number. (B) Clustering for 21 genes known to be regulated in cancer.
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restriction site. A pairwise comparison of differential hybridi-
zation is present for all the cell lines in Table W1 and at http://
bioinformatics.skcc.org/mcclelland/methylation.
Association of Some HpaII Fragment Hybridization
Differences with Methylation Differences
A difference in HpaII fragment hybridization intensity for
a promoter between genome samples can occur due to
methylation differences, differences in copy number, or re-
striction site polymorphisms. Global demethylation using
DAC [37] was used to determine which differences in hy-
bridization could be partially reversed, indicating methyla-
tion as the underlying cause. LNCaP cells were treated with
5-aza-cytidine for 72 hours during which they divided one to
two times. Untreated and treated cells were compared with
regards to their HpaII fragment profile for all the promoters
on the array (Figure 3A). The distribution was consistent
with differences in HpaII fragments, detecting a small reduc-
tion in DNA methylation for hundreds of genes. Figure 3B
plots 191 promoters that had appeared to be most signifi-
cantly ‘‘methylated’’ in LNCaP relative to at least one of three
normal prostate cell lines. Almost all of these genes showed
a shift to the right, consistent with demethylation, thus the
probability that HpaII fragment amplification differences had
correctly measured that these genes are methylated in
LNCaP. As a group, the shift of these genes to demethyl-
ation was highly significant (P < .001, Mann–Whitney U test).
To determine if HpaII fragment hybridization changes for
individual genes were due to a methylation change, MSP
was performed on 14 genes picked at random, which were
putatively differentially methylated between PC3M and
267B1 (Figure 4). Semiquantitative PCR was performed and
the proportion of methylation was estimated for each gene
and each sample. Eight of 14 were hypermethylated in PC3M
relative to 267B1, and one gene was hypermethylated in
267B1, confirming the array data. Of the remaining five genes
that showed no changes or changes in the wrong direction,
all were located on chromosome 5, which we will show later
to be due to a copy number change.
The ratio of HpaII fragment hybridization between two
different samples in microarrays is sometimes less than
that observed using specific PCR. The reason for this is
probably that many spots on the array report an intrinsically
relatively high level of hybridization from the complex probe,
despite the use of Cot1 subtraction. For example, most of
the control human spots that do not have restriction sites
still report a level of hybridization greater than nonhuman
controls. Thus, the reported difference in hybridization on the
microarray is generally a minimal estimate. Encouragingly,
however, 18.4% (504/2732) of promoter sequences on the
array that had two HpaII sites of the correct size appeared
to be differentially hybridized, compared to only 8.0% (28/
351) of human DNA that did not have HpaII sites (v2 = 23.2,
P < .001, chi-square analysis). The 28 exceptions have
similar sequences elsewhere in the genome, which may
cause cross-hybridization.
There are 504 promoters that showed statistically signif-
icant changes in hybridization among cancer and normal
prostate cell lines. Hierarchical clustering of the hybridization
patterns of these 504 promoters is displayed in Figure 5A
and the corresponding genes are listed in Table W1 in the
same order as they appear in the figure. The data are pre-
sented as a hybridization difference relative to RWPE-1, a
putatively normal transformed prostate epithelia cell from an
adult. The clustering of cell lines showed that PC3M-Pro4
and PC3M-LN4 are the most similar. Only one promoter,
HAS3, appeared more differentially hybridized between
PC3M-Pro4 and PC3M-LN4, possibly being hypermethyl-
ated in PC3M-Pro4. PC3M-Pro4 and PC3M-LN4 were clus-
tered with PC3M, then with PC3. These four cell lines were
less similar to LNCaP and normal cell lines. This is consistent
Table 2. Differential Hybridization of Amplified HpaII Fragments Near Genes
Known to be Methylation Targets in Cancer.*
RefSeq ID Gene Symbol Tumor Type
NM_004675 ARHI Breast cancer
NM_000633 bcl-2 Colorectal carcinoma
NM_007296 BRCA1 Breast cancer
Ovarian cancer
Cervical cancer
NM_000610 CD44 Prostate cancer
Colorectal cancer
Neuroblastoma
Gastric cancer
NM_000389 CDKN1A Prostate cancer
Lymphoma
Leukemia
NM_001262 CDKN2C Hodgkin’s lymphomas
NM_000125 ESR1 Prostate cancer
Colorectal cancer
Breast cancer
Lung cancer
NM_001924 GADD45A Breast cancer
NM_002451 MTAP Malignant melanoma
NM_000926 PGR Breast cancer
Cervical cancer
NM_002658 PLAU Prostate cancer
Breast cancer
NM_000965 RARB Prostate cancer
Testicular lymphoma
Cervical cancer
Breast cancer
Colorectal cancers
NM_006142 SFN Prostate cancer
Ovarian cancer
Skin cancer
Lung cancer
Oral cancer
Vulval cancer
Gastric cancer
Breast cancer
NM_000441 SLC26A4 Thyroid tumorigenesis
NM_003118 SPARC Pancreatic cancer
NM_003177 SYK Breast cancer
Gastric cancer
Ovarian cancer
T-lineage acute
lymphoblastic leukemia
NM_004817 TJP2 Pancreatic cancer
NM_000043 TNFRSF6 Prostate cancer
Bladder cancer
NM_003308 TSPY Prostate cancer
NM_004181 UCHL1 Pancreatic cancer
NM_015855 WIT-1 Acute myeloid leukemia
*References can be found in (Supplementary Table W2).
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with the origins of these cell lines. Among these 504 pro-
moters, eight genes are differentially hybridized in prostate
cancer cell lines relative to normal lines and are also known
as methylation-regulated genes in prostate cancer (CD44,
CDKN1A, ESR1, PLAU, RARB, SFN, TNFRSF6, and TSPY)
and 13 are known in other cancers (ARHI, bcl-2, BRCA1,
CDKN2C, GADD45A, MTAP, PGR, SLC26A4, SPARC,
SYK, TJP2, UCHL1, and WIT-1; Table 2 and Figure 5B).
The references for these observations are provided in a
supplementary version of Table 2. Methylation of SFN and
PLAU in LNCaP, but not PC3, has been reported before
[38,39], which is consistent with our data.
That an experiment involving three relatively normal
prostate lines and five prostate cancer cell lines pointed to
a large number of genes that were previously known to
be differentially methylated in cancer, particularly prostate
cancer, may indicate that methylation imprinting has been
maintained in culture. This provides further support for
the recent observation that cell lines and primary tumors
generally have similar overall distributions and frequen-
cies of gene methylation [40] and that prostate cancer cell
lines may have the same ‘‘hypermethylation fingerprint’’ as
primary and metastatic prostate cancers [36].
To date, almost all works on sequence-specific methyla-
tion have focused on the status of methylation in CpG
islands. Interestingly, 17.9% (90/504) of putative differential
methylation-regulated promoters in these prostate cell lines
were in the parts of promoters that do not have an obvious
CpG island. Table W1 includes a column indicating which
promoters on the array had CpG islands. A few of the
changes in promoter regions without CpG islands were con-
firmed (Figures 4 and 6). However, it remains possible that
copy number changes or restriction site polymorphisms may
explain some of those hybridization changes for other genes.
The gene TGFBR2 is differentially hybridized in LNCaP
relative to the other cell lines. Methylation of the TGFBR2
promoter was confirmed as present in LNCaP, and absent
in PC3, PC3M, PC3M-Pro4, PC3M-LN4, 267B1, RWPE-1,
and Mlcsv-40 by SQ-PCR across a promoter HpaII site
(data not shown). Inactivation of this gene by mutation is
common in many cancers, and could play a role in prostate
cancer [41]. Given that many genes inactivated by mutation
Figure 6. DNA copy number changes measured by CGH on promoter array. (A–C) Normalized HpaII fragment hybridization ratios for three different prostate
cancer cell lines compared to 267B1 plotted against the relative chromosomal position of each promoter. Candidate copy number changes are represented by grey
blocks. (A) LNCaP. (B) PC3. (C) PC3M. (D) PC3M (MspI ligation PCR), compared to 267B1 (MspI ligation PCR), against chromosomal position. (E) PC3M (RNA
expression level), compared to 267B1 RNA expression level, against chromosomal position.
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are also targets of methylation as an alternative method of
silencing [42,43], it was possible that TGFBR2 may be
methylated in some cancers or cancer cell lines. However,
differential methylation had not previously been observed
for this gene.
In cancer cell lines, relative to normal cell lines, there were
fewer genes that showed an increased HpaII fragment
hybridization, characteristic of copy number increases or hy-
pomethylation (251 promoters), versus a lower HpaII frag-
ment hybridization, characteristic of copy number decreases
or hypermethylation (286 promoters). An example of in-
creased HpaII fragment hybridization (hypomethylation or
copy number increase) in cancer lines is the promoter of
CTAG1, which is overexpressed in some lung and thyroid
cancers [44,45], although this overexpression has not been
attributed to hypomethylation or copy number changes.
Other than their dramatic differences in growth proper-
ties and metastatic ability [46,47], one of the most striking
differences between PC3M and LNCaP is that the latter is
almost unique among prostate cancer cell lines in still being
androgen-dependent. In this experiment, 29 genes showed
loss of hybridization in HpaII fragment in LNCaP and
19 genes showed loss of hybridization in PC3M, consistent
with hypermethylation or copy number loss. We looked for
differences in hybridization between PC3M and LNCaP
among 261 known and suspected androgen-regulated
genes present on the array [48]. Among known or suspected
androgen receptor–regulated genes that may be methyl-
ated or reduced in copy number in LNCaP relative to PC3M
were GG2-1 (TNF-induced protein) and GABARAPL2
(GABA(A) receptor–associated protein-like 2). In PC3M, the
list included FLJ13782 hypothetical protein, TSPY (testis-
specific protein, Y-linked), and RPS4Y (ribosomal protein S4,
Y-linked Y isoform).
Expression from the Y chromosome has been of interest
in prostate cancer [49,50] and changes in methylation of
EIF1AY,MGC26641,PRKY,RPS4Y,SHOX,TSPY, TSPYQ1,
and VCY are observed in our experiments, whereas the few
other Y chromosome genes on the array act as internal con-
trols for this observation because they are seemingly not
differentially methylated.
Correlation between RNA Expression and HpaII
Fragment Hybridization
The RNA expression levels of two cell lines, PC3M and
267B1, were obtained using Affymetrix U133AGeneChips. A
total of 51.6–53.5% of genes were called as present for
these samples. The Affymetrix U133A annotation table was
cross-referenced with our human promoter array by RefSeq
ID. When methylation differences are plotted against gene
expression differences between PC3M and 267B1 for all the
genes that showed HpaII fragment hybridization differences
and gene expression differences, there is a significant cor-
relation (40 genes, r = 0.68, P < .001; Figure 7 and Table 3).
The majority of genes that are differentially hybridized by
amplified HpaII fragments in the study are not considered in
Figure 7. Comparison of amplified HpaII fragment data to Affymetrix RNA expression data. Decreases in signal from HpaII fragments (which is usually due to an
increase in DNA methylation) between cell lines are generally associated with a decrease in RNA expression. The upper right quadrant contains genes with higher
RNA expressions in PC3M than in 267B1 and higher yields of HpaII fragments, in PC3M. The lower left quadrant contains genes with lower RNA expressions in
PC3M than in 267B1 and also lower yields of HpaII fragment hybridization in PC3M.
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this section because these genes happen not to be suffi-
ciently expressed, or their gene expression did not change
significantly. There are 27 genes, including three genes with
no apparent CpG island in the promoter region, that are less
hybridized by HpaII fragments (consistent with hypermeth-
ylation or copy number loss) in PC3M relative to 267B1 and
where gene expression was also downregulated in PC3M, as
would be expected if methylation or copy number loss is
associated with downregulation of expression. Nine genes,
including two genes with no CpG island in the promoter
region, were increased by HpaII fragments in hybridization
(consistent with hypomethylation or copy number increase)
in PC3M relative to 267B1, and the gene expression of these
genes is higher in PC3M, also as expected. There were only
four genes where the prediction of methylation or copy num-
ber loss was associated with an increase in gene expression
level. It will be of interest to explore these exceptions further.
CGH
The protocol (Figure 1) reports polymorphisms, changes
in DNA copy number, or DNA methylation status. This fea-
ture is also true of other array-based protocols that measure
methylation at multiple locations, simultaneously [15–19],
and at 2D gels (RLGS) [51]. Figure 6, A–C presents an
analysis of the HpaII ligation PCR data for three cell lines,
plotted in genome order, and essentially uses the data in the
same way as in the original representational analysis method
[9]. The best candidate chromosome regions for widespread
methylation or aneuploidy are highlighted. Note the dramatic
apparent aneuploidy of chromosome 5 in PC3M, which is
responsible for the identification, earlier in this manuscript, of
genes that appeared to be differentially methylated, but
which are, in fact, altered in copy number. Among the aneu-
ploidies seen here that have been previously reported are
changes in chromosome 6 in LNCaP, in chromosomes 8, 10,
and 14 in PC3 [28], and many sporadic changes previously
observed in prostate cancer [52]. The same analysis was
performed for each pair of cell lines; Table W1, which con-
tains 504 genes that are differentially hybridized among the
cell lines, was annotated to indicate cases where the dif-
ference in hybridization could be due to ploidy differences.
We also measured copy number changes in PC3M rela-
tive to 267B1 using MspI ligation PCR. MspI is an enzyme
that cuts at the same CCGG site as HpaII but which is
insensitive to methylation at most sites. The normalized ratio
(PC3M/267B1) was plotted against the chromosomal posi-
tion of each promoter (Figure 6D). This is a simple variation
on the CGH method [53]. Finally, the ratios of PC3M expres-
sion data relative to 267B1 were plotted against chromo-
some position in Figure 6E. Perhaps surprisingly, there are
detectable global effects of aneuploidy on averaged RNA
expression along the chromosomes.
Summary
Overall, we identified many candidate genes that were
rarely, if ever, previously associated with gene regulation by
methylation changes in cancer. These genes include PAK6
(p21-activated protein kinase 6), RAD50 (RAD50 homolog
isoform 1), TLX3 (T-cell leukemia, homeo box 3), PIR51
(RAD51-interacting protein), MAP2K5 (mitogen-activated
protein kinase kinase 5 isoform B), INSR (insulin recep-
tor), FBN1 (fibrillin 1), and GG2-1 (TNF-induced protein).
Many genes have exciting functions that could be plausibly
associated with cancer progression, but we will not speculate
further on those roles here. These genes will be worthy of
Table 3. Promoters That Show Large Differences in Both HpaII Fragment
Amplification and RNA Expression, between PC3M and 267B1.
RefSeq ID Gene
Symbol
Gene Full
Name
Expression
Ratio*
Genes with reduced HpaII fragment hybridization in PC3M
(candidate hypermethylated genes)
NM_000138 FBN1 Fibrillin 1 5.21
NM_000546 TP53 Tumor protein p53 4.66
NM_000985 RPL17 Ribosomal protein L17 1.17
NM_001008 RPS4Yy Ribosomal protein S4,
Y-linked Y isoform
6.36
NM_001790 CDC25C Cell division cycle 25C protein,
isoform a
2.29
NM_002082 GPRK6 G protein–coupled receptor
kinase 6
1.76
NM_002749 MAPK7 Mitogen-activated protein
kinase 7 isoform 1
1.62
NM_003118 SPARCy Secreted protein, acidic,
cysteine-rich (osteonectin)
4.28
NM_003714 STC2 Stanniocalcin 2 1.42
NM_003999 OSMR Oncostatin M receptor 2.52
NM_004472 FOXD1y Forkhead box D1 2.68
NM_004663 RAB11A RAB11A, member RAS
oncogene family
1.13
NM_004701 CCNB2 Cyclin B2 1.78
NM_005509 DMXL1 Dmx-like 1 1.37
NM_005732 RAD50 RAD50 homolog isoform 1 2.69
NM_005983 SKP2 S-phase kinase–associated
protein 2 isoform 1
1.47
NM_006282 STK4 Serine/threonine kinase 4 1.36
NM_006479 PIR51 RAD51-interacting protein 1.97
NM_012382 OSRF Osmosis-responsive factor 2.36
NM_014621 HOXD4 Homeo box D4 3.07
NM_018163 FLJ10634 Hypothetical protein FLJ10634 1.66
NM_018268 FLJ10904 Hypothetical protein FLJ10904 4.17
NM_024501 HOXD1 Homeo box D1 1.61
NM_024558 C14orf138 Hypothetical protein FLJ13920 1.56
NM_024796 FLJ22639 Hypothetical protein FLJ22639 1.00
NM_033028 BBS4 Bardet-Biedl syndrome 4 1.54
NM_133338 RAD17 RAD17 homolog isoform 1 1.63
NM_006194 PAX9z Paired box gene 9 2.55
NM_053001 OSR2z Odd-skipped– related 2A protein 1.43
Genes with increased HpaII fragment hybridization in PC3M
(candidate hypomethylated genes)
NM_001123 ADK Adenosine kinase isoform a 1.69
NM_002290 LAMA4 Laminin, alpha 4 precursor 2.11
NM_002467 MYC v-myc myelocytomatosis viral
oncogene homolog
2.51
NM_002658 PLAU Plasminogen activator, urokinase 1.75
NM_004693 K6HFy Cytokeratin type II 9.27
NM_005555 KRT6By Keratin 6B 1.10
NM_006142 SFN Stratifin 5.60
NM_030759 NRBF-2 Nuclear receptor binding factor-2 1.45
NM_032804 FLJ14547 Hypothetical protein FLJ14547 2.39
NM_018649 H2AFY2z Core histone macroH2A2.2 2.02
NM_020177 FEM1Cz Feminization 1 homolog a 1.30
*Ratios: log2(PC3M/267B1).
yPromoter does not have a CpG island within the amplified promoter region.
zPromoter where HpaII fragment hybridization was not correlated with RNA
expression level.
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assessment in tumors by methods that assay individual
genes, such as bisulfite sequencing.
Relying on cleavage by enzymes that detect methylation
[15–19,51] has limitations, including the need to parse out
copy number and SNPs at a subsequent step. In addition,
tumor samples are usually mixtures of various cell types, in
addition to tumor cells. However, the protocol can use very
little DNA. It is a future goal to demonstrate that enriched
tumor samples can be assayed by this class of methods.
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